Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
百慕大漢密爾頓，2024年4月4日（GLOBE NEWSWIRE）——提供基於納米顆粒技術的公司Altamira Therapeutics Ltd.（“Altamira” 或 “公司”）（納斯達克股票代碼：CYTO）今天宣佈，將於2024年4月10日星期五舉行2023年全年財務業績和業務更新電話會議。創始人、董事長兼首席執行官托馬斯·邁耶和首席運營官科瓦東加·帕內達將發表準備好的講話，隨後是問答環節，他們將回答投資者和分析師的問題。
Webcast Access:
網絡直播接入：
- Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update Call
- Date: Wednesday, April 10, 2024
- Time: 8:30 am EDT
- Webcast URL: https://edge.media-server.com/mmc/p/ijjfu6tm
- 活動：Altamira Therapeutics 2023年全年財務業績和業務更新電話會議
- 日期：2024 年 4 月 10 日星期三
- 時間：美國東部時間上午 8:30
- 網絡直播網址： https://edge.media-server.com/mmc/p/ijjfu6tm
Registration for Call:
電話註冊：
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call.
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click "Call Me" for an immediate callback from the system. The call will come from a US number.
- 註冊後，您將收到撥入信息和用於加入通話的唯一 PIN 以及一封包含詳細信息的確認電子郵件。
- 選擇加入通話的方法。
- 撥入：顯示撥入號碼和唯一的 PIN，可直接從您的電話連接。
- 給我打電話：輸入您的電話號碼，然後單擊 “給我打電話”，系統會立即進行回電。該電話將來自美國的號碼。
A replay of the call will be available after the live event and accessible through the webcast link: https://edge.media-server.com/mmc/p/ijjfu6tm
電話會議將在直播結束後重播，可通過網絡直播鏈接觀看： https://edge.media-server.com/mmc/p/ijjfu6tm
About Altamira Therapeutics
關於阿爾塔米拉療法
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore / SemaPhore platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in its commercial-stage legacy asset Bentrio, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen and Sonsuvi for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com
Altamira Therapeutics（納斯達克股票代碼：CYTO）正在開發和提供基於肽的納米顆粒技術，用於將RNA高效輸送到肝外組織（Oligophore/SemaPhore平台）。該公司目前有兩個使用其專有交付技術的旗艦siRNA項目：用於KRAS驅動的癌症的 AM-401 和用於類風溼關節炎的 AM-411，均在體內概念驗證以外的臨床前開發中。多功能交付平台還適用於mRNA和其他 RNA 模式，並通過外包許可提供給制藥或生物技術公司。此外，阿爾塔米拉持有其商業階段遺留資產Bentrio49％的股份（還有額外的經濟權利），Bentrio是一種治療過敏性鼻炎的非處方鼻腔噴霧劑。此外，該公司正在合作/剝離其內耳遺留資產（用於眩暈的 AM-125 鼻腔噴霧劑；第二階段後；Keyzilen和Sonsuvi用於耳鳴和聽力損失；第三階段）。Altamira成立於2003年，總部位於百慕大漢密爾頓，主要業務位於瑞士巴塞爾。欲了解更多信息，請訪問：https://altamiratherapeutics.com
Investor Contact
Hear@altamiratherapeutics.com